Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses: 2012-2024

Historic Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $235.5 million.

  • Ocular Therapeutix's Operating Expenses rose 35.52% to $83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.6 million, marking a year-over-year increase of 51.27%. This contributed to the annual value of $235.5 million for FY2024, which is 67.23% up from last year.
  • As of FY2024, Ocular Therapeutix's Operating Expenses stood at $235.5 million, which was up 67.23% from $140.8 million recorded in FY2023.
  • Ocular Therapeutix's Operating Expenses' 5-year high stood at $235.5 million during FY2024, with a 5-year trough of $80.2 million in FY2020.
  • Its 3-year average for Operating Expenses is $168.8 million, with a median of $140.8 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first declined by 10.86% in 2020, then spiked by 67.23% in 2024.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Operating Expenses stood at $80.2 million in 2020, then spiked by 51.48% to $121.6 million in 2021, then increased by 7.07% to $130.1 million in 2022, then climbed by 8.20% to $140.8 million in 2023, then soared by 67.23% to $235.5 million in 2024.